Pancreatic cancer is one of the deadliest cancers, but work being conducted by a team of University of Georgia researchers aims to help physicians diagnose the disease early, when it?s more easily treated.
It?s yet another example of how a good thing can go bad: Researchers have found evidence in laboratory studies that ?good? cholesterol, renowned for its ability to protect against heart disease, can undergo detrimental changes in protein composition that make it ?bad? for the heart.
Groundbreaking research from the University of Melbourne has shed new light on why long term drug users find it hard to say no, despite dire consequences to their health.
A change to the Pharmaceutical Benefits scheme (PBS) from 1 October 2007 will provide subsidised access to adults and children of Remicade? (infliximab) for the treatment of Crohn?s disease.
Research led by the University of Warwick into the genomes of two bacteria could save orchards from a previously almost incurable disease, and also assist in treating complications arising from human blood transfusions.
Computer analysis of existing drugs may be key to fighting new infectious agents and antibiotic-resistant pathogens like deadly tuberculosis strains and staph “superbugs.” Researchers in Canada say the use of such “emergency discovery” technology could save time, money and lives during a sudden outbreak or a bioterrorism attack. The study will be presented in August at the American Chemical Society national meeting in Boston.
Advanced supply contracts to provide the vaccine for a possible flu pandemic were today awarded by the Department of Health to pharmaceutical company GSK and Baxter Healthcare.
Shire BioChem Inc. announced that it is pleased to support Canada?s Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture in Canada a generic fixed dose triple combination antiretroviral medicine that contains a drug (3TC?) over which Shire BioChem Inc. holds patent rights in Canada.
GlaxoSmithKline (GSK) announced that it has entered into an agreement with the UK Government to provide its pandemic influenza vaccine in the event of a flu pandemic. It is one of the largest contracts signed by GSK to date for its proprietary adjuvanted pandemic flu vaccine.
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.